the value of patient's time in cancer medicine || three oncologists discuss
Published 3 years ago • 1.2K plays • Length 18:21Download video MP4
Download video MP3
Similar videos
-
26:07
the problem with the evidence in cancer medicine
-
25:38
practicing at the edge of oncology || chris booth, aaron goodman, vinay prasad discuss
-
33:08
neither smart; nor the start; useless phase 2 pad cvs but don't help cancer patients
-
43:05
old fashioned intelligence in cancer medicine
-
55:18
lecture on cancer [ coffee/ cancer; ev pembro; censoring] to ucsf fresno
-
33:06
are rcts needed for new cancer drugs? | two oncologists discuss
-
44:12
malignant book club - episode 3 - conflicts of interest in cancer care/ hype/ spin and more
-
25:40
nutrition science is entirely unreliable | don't trust the new york times well section
-
17:45
should boys play football? the new england journal of parenting weighs in
-
10:05
joe rogan, ivermectin, sanjay gupta, cnn, the culture war | a doctor reflects on the evidence
-
2:04
why cancer stands apart: unveiling the complexity of the disease
-
29:55
the crushing cost of cancer drugs | a lecture
-
19:02
oncologists are sacrificing common sense in pursuit of innovation | invited lecture
-
37:23
driver mutation lung cancer
-
2:12:04
#133 - vinay prasad, m.d., m.p.h: hallmarks of successful cancer policy
-
1:01:30
3.48 the predictive value of high tumor mutational burden with dr. luc morris
-
31:53
lecture 2 - surrogate endpoints in oncology - reading and interpreting cancer trials
-
12:12
checkmate 274 adjuvant nivolumab in urothelial cancer | an oncologist's take
-
9:46
cassiopeia part 2 - not the constellation | an oncologist breaks down the randomized trial
-
25:56
bad karma - an analysis of karmma-3 | idacel vs 'standard regimens'
-
47:08
lecture 3 - fda drug approval 101- reading and interpreting cancer trials series
-
1:31:47
3.04 listener questions & medtwitter and risk benefit profile of ramucirumab with dr. bishal gyawali